Aug 18, 2016

BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290 read more...

Aug 10, 2016

BeiGene Reports Second Quarter 2016 Financial Results read more...

Jul 05, 2016

BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China read more...

Jun 29, 2016

BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 read more...

Jun 06, 2016

BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference read more...

Jun 05, 2016

BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting read more...

May 19, 2016

BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting read more...

May 11, 2016

BeiGene Reports First Quarter 2016 Financial Results read more...

May 04, 2016

BeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development read more...

Apr 17, 2016

BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting read more...

Apr 11, 2016

BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer read more...

Feb 08, 2016

BeiGene Announces Closing of Its Initial Public Offering read more...

News Details